Welcome to our dedicated page for Verastem news (Ticker: VSTM), a resource for investors and traders seeking the latest updates and insights on Verastem stock.
Verastem, Inc. (Verastem Oncology, Nasdaq: VSTM) is a biopharmaceutical company focused on RAS/MAPK pathway-driven cancers, and its news flow reflects both commercial progress and active clinical development. Company press releases emphasize the U.S. launch and ongoing adoption of AVMAPKI FAKZYNJA CO-PACK, an FDA-approved combination of avutometinib and defactinib for adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer, as well as updates on confirmatory and expansion trials built around this therapy.
Investors following VSTM news can expect regular updates on clinical trial milestones, including the Phase 3 RAMP 301 confirmatory study in recurrent LGSOC, the RAMP 205 trial in first-line metastatic pancreatic cancer, and the now-discontinued RAMP 203 study in KRAS G12C-mutated NSCLC. Verastem also issues detailed communications on early-stage programs such as VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, covering dose-escalation progress, preliminary safety and efficacy signals, and combination strategies with agents like cetuximab.
Beyond clinical data, Verastem’s news includes capital markets events such as public offerings of common stock and pre-funded warrants, as well as corporate updates on leadership changes and participation in healthcare and investor conferences. These announcements provide context on how the company is funding and prioritizing its RAS/MAPK-focused portfolio.
Stock Titan’s VSTM news page aggregates these company-issued releases and related coverage into a single, organized feed. Readers can use this page to track developments in AVMAPKI FAKZYNJA CO-PACK commercialization, monitor progress of key trials like RAMP 301 and VS-7375-101, and follow Verastem’s financing and strategic communications over time.
Verastem Oncology (Nasdaq: VSTM) announced inducement equity awards for new hires under Nasdaq Listing Rule 5635(c)(4). The company granted stock options to purchase 73,000 shares to eight new employees and 218,265 restricted stock units to nineteen new employees, totaling 291,265 potential shares.
The stock options have an exercise price of $6.88, equal to the closing Nasdaq price on January 6, 2026. Awards vest 25% on the one-year anniversary of hire, with the remainder vesting in equal quarterly installments over the following three years, subject to continued service.
Verastem Oncology (Nasdaq: VSTM) will discontinue the RAMP 203 Phase 1/2 trial in advanced KRAS G12C NSCLC and stop further enrollment to reallocate resources to clinical development of VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, and the RAMP 205 program. As of the November 26, 2025 data cutoff, 66 patients treated at the RP2D were evaluable. Key efficacy readouts: doublet, treatment-naïve ORR 40% (12/30) with mPFS 11.1 months; doublet, previously treated ORR 9.5% (2/21) with mPFS 3.7 months; triplet, treatment-naïve ORR 50% (2/4); VS-7375 showed a 69% response rate (11/16) in KRAS G12D NSCLC. No dose-limiting toxicities observed; most common TRAEs were nausea 56.8%, diarrhea 52.7%, and fatigue 45.9%.
Verastem Oncology (Nasdaq: VSTM) announced executive changes and clinical progress to accelerate growth. Michael Kauffman, M.D., Ph.D. moves from lead director to President of Development and joins the executive team; John Johnson is appointed Chairman of the Board. The company said COO Matthew Ros will depart as responsibilities are reallocated.
Commercial launch activity for AVMAPKI FAKZYNJA CO-PACK has begun and the international Phase 3 confirmatory trial RAMP 301 completed an additional enrollment of 29 patients; topline primary-endpoint results are expected in mid-2027. The company remains blinded to the interim analysis results.
Verastem Oncology (Nasdaq: VSTM) announced that its management team will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025 at 10:25 AM ET in Miami, Florida.
A live webcast will be available under “Events & Presentations” on the company website at www.verastem.com, and a replay will be archived on the site for approximately 90 days following the presentation.
Verastem Oncology (Nasdaq: VSTM) priced an underwritten public offering to raise approximately $90 million gross. The company will sell 8,543,794 common shares at $7.25 per share and, in lieu of common stock to certain investors, 3,870,000 pre-funded warrants at $7.2499 each (with a $0.0001 exercise price).
The underwriters have a 30-day option for up to 1,862,069 additional common shares. The offering is expected to close on or about November 17, 2025. Net proceeds are intended to fund commercial activities for AVMAPKI FAKZYNJA co-pack (FDA approved for KRAS-mutated recurrent low-grade serous ovarian cancer), continued R&D including the VS-7375 KRAS G12D program, and general corporate purposes.
Verastem Oncology (Nasdaq: VSTM) announced a proposed underwritten public offering of its common stock, with underwriters granted a 30-day option to buy up to an additional 15% of shares. The offering is subject to market conditions and may not be completed.
Verastem said it will use net proceeds to fund commercial activities for the FDA-approved AVMAPKI FAKZYNJA co-pack for KRAS-mutated recurrent low-grade serous ovarian cancer, continue clinical R&D including the VS-7375 KRAS G12D program, and for working capital. A Form S-3 shelf was declared effective on Nov 20, 2023.
Verastem Oncology (Nasdaq: VSTM) said its management team will present at two investor conferences in November 2025: a Guggenheim Healthcare Conference fireside chat on Tuesday, November 11 at 1:00 pm ET, and a Jefferies Global Healthcare Conference fireside chat in London on Wednesday, November 19 at 2:30 pm GMT (9:30 am ET).
A live webcast of both fireside chats will be available under Events & Presentations on the company investor website and replays will be archived for approximately 90 days after each presentation.
Verastem Oncology (Nasdaq: VSTM) reported Q3 2025 results and business updates on November 4, 2025. Key commercial and clinical highlights include $11.2M net product revenue in the first full quarter post-launch of AVMAPKI FAKZYNJA CO-PACK, completion of planned enrollment for the Phase 3 RAMP 301 trial (270 patients) with an IDMC-recommended one-time +29 patient increase, and VS-7375 clearing 400 mg and 600 mg monotherapy doses with no dose-limiting toxicities.
Financials: total operating expenses $52.0M, GAAP net loss $98.5M (loss per share $1.35), non-GAAP adjusted net loss $39.4M, and cash, cash equivalents and investments of $137.7M, with runway into H2 2026 assuming product revenue and warrant exercises.
Verastem Oncology (Nasdaq: VSTM) reported encouraging preliminary Phase 1/2a data for oral KRAS G12D inhibitor VS-7375. The 400 mg QD and 600 mg QD monotherapy dose levels cleared with no dose-limiting toxicities observed and no nausea, vomiting, or diarrhea > Grade 1 at those doses. Of five efficacy-evaluable patients with at least one scan, 4 of 5 showed tumor reduction and remain on treatment. The study has opened a dose-escalation cohort at 900 mg QD and initiated enrollment of a combination cohort of VS-7375 with cetuximab including colorectal cancer patients. An interim safety and efficacy update is planned for first half of 2026.
Verastem Oncology (Nasdaq: VSTM) will report third quarter 2025 financial results and business updates on Tuesday, November 4, 2025 at 8:00 AM ET. The company will host a conference call and live audio webcast with accompanying slides available in the Investor "Events & Presentations" section at https://investor.verastem.com/events.
Dial-in details: (888) 596-4144 (U.S.) or (646) 968-2525 (international); enter passcode 8194537 at least 10 minutes before the call. A replay of the webcast will be archived and available after the event.
FAQ
What is the current stock price of Verastem (VSTM)?
What is the market cap of Verastem (VSTM)?
